Abstract: In a chamber, first processing is performed as preliminary processing. After the first processing has been finished, the temperature in a predetermined target region in the chamber is measured with a thermographic camera. Then, whether or not to start second processing on a substrate is determined in accordance with the acquired measured temperature information. If it is determined as a result that the second processing can be started, the second processing is performed. In this case, the second processing on the substrate can be started, with the temperature of the target region in the chamber having reached its stability. Accordingly, the second processing can be performed uniformly on a plurality of substrates. That is, it is possible to reduce variations in processing caused by temperature environments in the chamber.

Abstract: A vehicle lighting device includes a high-light source group, a low-light source group, a high-beam lens to transmit light from the high-beam light source and emit the light to outside, a low-beam lens to transmit light from the low-beam light source and emit the light to outside, a circuit board having the high-beam light source and the low-beam light source mounted thereon together, and a reflector that guides light emitted from the low-beam light source to the low-beam lens, where the circuit board is inclined in a front-rear direction and an up-down direction.

Abstract: A differential device includes: an input member; a case member arranged coaxially with the input member; a one-way clutch arranged between the input member and the case member and transmitting torque therebetween only when the input member attempts to rotate in a normal rotation direction; a pinion gear supported by the case member to rotate about the axis perpendicular to the center axis of the case member; and a pair of side gears supported coaxially with the input member to rotate relative to the input member and the case member and meshing with the pinion gear.

Abstract: Provided is an anti-EphA4 antibody capable of binding to EphA4 and enhancing the cleavage of EphA4, and a pharmaceutical composition comprising the antibody as an active ingredient. The anti-EphA4 antibody comprises a heavy chain comprising a heavy chain CDR1 of SEQ ID NO: 30; a heavy chain CDR2 of SEQ ID NO: 31; and a heavy chain CDR3 of SEQ ID NO: 32; and a light chain comprising a light chain CDR1 of SEQ ID NO: 33; a light chain CDR2 of SEQ ID NO: 34; and a light chain CDR3 of SEQ ID NO: 35, or a heavy chain comprising a heavy chain CDR1 of SEQ ID NO: 42; a heavy chain CDR2 of SEQ ID NO: 31; and a heavy chain CDR3 of SEQ ID NO: 43; and a light chain comprising a light chain CDR1 of SEQ ID NO: 44; a light chain CDR2 of SEQ ID NO: 34; and a light chain CDR3 of SEQ ID NO: 35.

Abstract: A differential device includes: an input member; a case member arranged coaxially with the input member; a one-way clutch arranged between the input member and the case member and transmitting torque therebetween only when the input member attempts to rotate in a normal rotation direction; a pinion gear supported by the case member to rotate about the axis perpendicular to the center axis of the case member; and a pair of side gears supported coaxially with the input member to rotate relative to the input member and the case member and meshing with the pinion gear.

Abstract: An output shaft is configured by connecting a first shaft and a second shaft, coaxially arranged with each other, by a reverse input cutoff clutch 20; an end portion on one side in an axial direction of the second shaft located on an opposite side from the first shaft with a gear portion sandwiched in between in the axial direction being rotatably supported with respect to a fixed portion by a bearing device; the reverse input cutoff clutch having a function that, when rotational torque is input to the first shaft, transmits the rotational torque input to the first shaft to the second shaft, and when rotational torque is reversely input to the second shaft, completely cuts off the rotational torque reversely input to the second shaft and does not transmit the rotational torque to the first shaft, or transmits part of the rotational torque to the first shaft and cuts off the remaining portion.

Abstract: The rotation transmission state switching device comprises a clutch device comprising a first rotating member having a first-rotating-member-side engaging portion, a second rotating member having a second-rotating-member-side engaging portion, a third rotating member having a third-rotating-member-side engaging portion; and an engaging element having an engaging-element-side first engaging portion engaging with the first-rotating-member-side engaging portion, an engaging-element-side second engaging portion engaging with the second-rotating-member-side engaging portion, and an engaging-element-side third engaging portion engaging with the third-rotating-member-side engaging portion; and a restriction device configured to switch between allowing and restricting rotation of the first rotating member, allowing or preventing torque transmission between the second rotating member and the third rotating member.

Abstract: The rotation transmission state switching device comprises a clutch device comprising a first rotating member having a first-rotating-member-side engaging portion, a second rotating member having a second-rotating-member-side engaging portion, a third rotating member having a third-rotating-member-side engaging portion; and an engaging element having an engaging-element-side first engaging portion engaging with the first-rotating-member-side engaging portion, an engaging-element-side second engaging portion engaging with the second-rotating-member-side engaging portion, and an engaging-element-side third engaging portion engaging with the third-rotating-member-side engaging portion; and a restriction device configured to switch between allowing and restricting rotation of the first rotating member, allowing or preventing torque transmission between the second rotating member and the third rotating member.

Abstract: A 3D model evaluation system includes: a loading unit that loads 3D model data created by 3D CAD; a history checking unit that checks a creation history which is added to the 3D model data loaded by the loading unit and which is obtained in a case where the 3D model data is created by the 3D CAD; and an evaluation unit that evaluates a degree of coincidence between the creation history of the 3D model data checked by the history checking unit and a predetermined rule.

Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.

Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.

Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.

Abstract: A 3D model evaluation system includes: a loading unit that loads 3D model data created by 3D CAD; a history checking unit that checks a creation history which is added to the 3D model data loaded by the loading unit and which is obtained in a case where the 3D model data is created by the 3D CAD; and an evaluation unit that evaluates a degree of coincidence between the creation history of the 3D model data checked by the history checking unit and a predetermined rule.

Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.

Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.

Abstract: A toroidal continuously variable transmission includes a preload spring disposed between a rotary assembly including a first disc and a pressing device, and a driving force transmission shaft, and a thrust bearing disposed between a first member and the preload spring, the first member being one of the rotary assembly and the driving force transmission shaft. In a direction of an axis line, a gap is formed between a second member and the thrust bearing, the second member being the other of the rotary assembly and the driving force transmission shaft. A dimension of the gap in the direction of the axis line is less than a deformation amount of the preload spring in the direction of the axis line, at an elastic limit.

Abstract: It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.

Abstract: A toroidal continuously variable transmission includes a preload spring disposed between a rotary assembly including a first disc and a pressing device, and a driving force transmission shaft, and a thrust bearing disposed between a first member and the preload spring, the first member being one of the rotary assembly and the driving force transmission shaft. In a direction of an axis line, a gap is formed between a second member and the thrust bearing, the second member being the other of the rotary assembly and the driving force transmission shaft. A dimension of the gap in the direction of the axis line is less than a deformation amount of the preload spring in the direction of the axis line, at an elastic limit.

Abstract: It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.

Abstract: Projections protruding towards a cam plate and a disc are provided on both axial side surfaces of the retainer at a plurality of positions at which phases of the projections in the circumferential direction are offset from pockets. One axial direction surface of the cam plate and the disc are formed with concave portions at portions facing the respective projections. The concave portions have an axial depth deepest at a center portion thereof in the circumferential direction and becoming shallower towards both end portions thereof.